Mind Medicine (MindMed)NASDAQ: MNMD

Mind Medicine's share price has responded very strongly to a third quarter update that contained very little new information. The market appears to have moved to a bullish stance following confirmation that clinical timelines have not been changed. With a key competitor recently running into difficulties, Mind Medicine may now be the favored play in the psychedelics sector.

Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter.

The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed. Min.

The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing market volatility and uncertainty for psychedelic stocks. Major psychedelic stocks like MindMed have the fundamentals and growing FDA support to withstand a negative FDA decision on MDMA therapy.

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27,.

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. “Following a constructive En.

Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.